Cantor Fitzgerald Comments on Septerna FY2025 Earnings

Septerna, Inc. (NASDAQ:SEPN) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Septerna in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.58) for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share.

SEPN has been the topic of a number of other reports. TD Cowen assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a “buy” rating on the stock. Wells Fargo & Company assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price target for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target on the stock.

Septerna Stock Performance

Septerna stock opened at $19.38 on Thursday. The stock has a 50-day moving average price of $22.49. Septerna has a 1-year low of $15.86 and a 1-year high of $28.99.

Institutional Trading of Septerna

An institutional investor recently bought a new position in Septerna stock. SG Americas Securities LLC acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 8,095 shares of the company’s stock, valued at approximately $185,000.

Insider Activity

In related news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the acquisition, the insider now directly owns 6,215,591 shares in the company, valued at approximately $111,880,638. The trade was a 6.34 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.